These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 26350813

  • 1. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans.
    Wassef H, Bissonnette S, Saint-Pierre N, Lamantia V, Cyr Y, Chrétien M, Faraj M.
    J Clin Lipidol; 2015; 9(5):664-75. PubMed ID: 26350813
    [Abstract] [Full Text] [Related]

  • 2. Inter-relationships between proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III and plasma apolipoprotein B-48 transport in obese subjects: a stable isotope study in the postprandial state.
    Chan DC, Wong AT, Pang J, Barrett PH, Watts GF.
    Clin Sci (Lond); 2015 Mar; 128(6):379-85. PubMed ID: 25291660
    [Abstract] [Full Text] [Related]

  • 3. ApoB-lipoproteins and dysfunctional white adipose tissue: Relation to risk factors for type 2 diabetes in humans.
    Lamantia V, Bissonnette S, Wassef H, Cyr Y, Baass A, Dufour R, Rabasa-Lhoret R, Faraj M.
    J Clin Lipidol; 2017 Mar; 11(1):34-45.e2. PubMed ID: 28391908
    [Abstract] [Full Text] [Related]

  • 4. High plasma apolipoprotein B identifies obese subjects who best ameliorate white adipose tissue dysfunction and glucose-induced hyperinsulinemia after a hypocaloric diet.
    Bissonnette S, Saint-Pierre N, Lamantia V, Leroux C, Provost V, Cyr Y, Rabasa-Lhoret R, Faraj M.
    Am J Clin Nutr; 2018 Jul 01; 108(1):62-76. PubMed ID: 29917037
    [Abstract] [Full Text] [Related]

  • 5. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
    Vergès B, Duvillard L, Brindisi MC, Gautier E, Krempf M, Costet P, Cariou B.
    Atherosclerosis; 2011 Nov 01; 219(1):342-8. PubMed ID: 21889145
    [Abstract] [Full Text] [Related]

  • 6. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
    Guardiola M, Plana N, Ibarretxe D, Cabré A, González M, Ribalta J, Masana L.
    Clin Sci (Lond); 2015 Jun 01; 128(12):877-82. PubMed ID: 25649668
    [Abstract] [Full Text] [Related]

  • 7. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.
    Kwakernaak AJ, Lambert G, Dullaart RP.
    Clin Biochem; 2012 Nov 01; 45(16-17):1522-4. PubMed ID: 22809551
    [Abstract] [Full Text] [Related]

  • 8. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients.
    Kappelle PJ, Lambert G, Dullaart RP.
    Atherosclerosis; 2011 Feb 01; 214(2):432-5. PubMed ID: 21122860
    [Abstract] [Full Text] [Related]

  • 9. Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects.
    Kwakernaak AJ, Lambert G, Muller Kobold AC, Dullaart RP.
    Thyroid; 2013 Feb 01; 23(2):166-72. PubMed ID: 23106476
    [Abstract] [Full Text] [Related]

  • 10. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S, Xu RX, Guo YL, Zhang Y, Zhu CG, Sun J, Li JJ.
    Nutr Metab Cardiovasc Dis; 2015 Apr 01; 25(4):411-7. PubMed ID: 25466598
    [Abstract] [Full Text] [Related]

  • 11. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A, Kappelle PJ, Lambert G, Dullaart RP.
    Arch Med Res; 2012 Jan 01; 43(1):11-4. PubMed ID: 22300679
    [Abstract] [Full Text] [Related]

  • 12. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
    Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H, Harada-Shiba M.
    J Clin Endocrinol Metab; 2015 Jan 01; 100(1):E41-9. PubMed ID: 25313916
    [Abstract] [Full Text] [Related]

  • 13. The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.
    Ooi TC, Krysa JA, Chaker S, Abujrad H, Mayne J, Henry K, Cousins M, Raymond A, Favreau C, Taljaard M, Chrétien M, Mbikay M, Proctor SD, Vine DF.
    J Clin Endocrinol Metab; 2017 Sep 01; 102(9):3452-3460. PubMed ID: 28673045
    [Abstract] [Full Text] [Related]

  • 14. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects.
    Kappelle PJ, Lambert G, Dahlbäck B, Nielsen LB, Dullaart RP.
    Atherosclerosis; 2011 Feb 01; 214(2):492-4. PubMed ID: 21122852
    [Abstract] [Full Text] [Related]

  • 15. PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program.
    Arsenault BJ, Pelletier-Beaumont E, Alméras N, Tremblay A, Poirier P, Bergeron J, Després JP.
    Atherosclerosis; 2014 Oct 01; 236(2):321-6. PubMed ID: 25128757
    [Abstract] [Full Text] [Related]

  • 16. Plasma proprotein convertase subtilisin kexin type 9 is not altered in subjects with impaired glucose metabolism and type 2 diabetes mellitus, but its relationship with non-HDL cholesterol and apolipoprotein B may be modified by type 2 diabetes mellitus: The CODAM study.
    Brouwers MC, Troutt JS, van Greevenbroek MM, Ferreira I, Feskens EJ, van der Kallen CJ, Schaper NC, Schalkwijk CG, Konrad RJ, Stehouwer CD.
    Atherosclerosis; 2011 Jul 01; 217(1):263-7. PubMed ID: 21497351
    [Abstract] [Full Text] [Related]

  • 17. A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts.
    Gauthier MS, Pérusse JR, Awan Z, Bouchard A, Tessier S, Champagne J, Krastins B, Byram G, Chabot K, Garneau P, Rabasa-Lhoret R, Faubert D, Lopez MF, Seidah NG, Coulombe B.
    Methods; 2015 Jun 15; 81():66-73. PubMed ID: 25770357
    [Abstract] [Full Text] [Related]

  • 18. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P, Stenman UH, Gylling H.
    Clin Sci (Lond); 2015 Sep 15; 129(5):439-46. PubMed ID: 25857271
    [Abstract] [Full Text] [Related]

  • 19. Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor.
    Sun H, Samarghandi A, Zhang N, Yao Z, Xiong M, Teng BB.
    Arterioscler Thromb Vasc Biol; 2012 Jul 15; 32(7):1585-95. PubMed ID: 22580899
    [Abstract] [Full Text] [Related]

  • 20. Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome.
    Cyr Y, Lamantia V, Bissonnette S, Burnette M, Besse-Patin A, Demers A, Wabitsch M, Chrétien M, Mayer G, Estall JL, Saleh M, Faraj M.
    Physiol Rep; 2021 Feb 15; 9(3):e14721. PubMed ID: 33527668
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.